Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
URGN

URGN - UroGen Pharma Ltd Stock Price, Fair Value and News

15.83USD-0.81 (-4.87%)Market Closed

Market Summary

URGN
USD15.83-0.81
Market Closed
-4.87%

URGN Alerts

  • Point72 Asset Management, L.P. reported owning 6.2% of URGN [2024-06-24]

URGN Stock Price

View Fullscreen

URGN RSI Chart

URGN Valuation

Market Cap

571.9M

Price/Earnings (Trailing)

-5.48

Price/Sales (Trailing)

6.78

EV/EBITDA

-5.4

Price/Free Cashflow

-6.93

URGN Price/Sales (Trailing)

URGN Profitability

Operating Margin

89.53%

EBT Margin

-119.05%

Return on Equity

259.92%

Return on Assets

-52.01%

Free Cashflow Yield

-14.42%

URGN Fundamentals

URGN Revenue

Revenue (TTM)

84.3M

Rev. Growth (Yr)

9.24%

Rev. Growth (Qtr)

-20.18%

URGN Earnings

Earnings (TTM)

-104.3M

Earnings Growth (Yr)

-6.86%

Earnings Growth (Qtr)

-24.1%

Breaking Down URGN Revenue

Last 7 days

-6.5%

Last 30 days

-6.2%

Last 90 days

15.3%

Trailing 12 Months

56.1%

How does URGN drawdown profile look like?

URGN Financial Health

Current Ratio

7.47

Debt/Equity

-2.43

Debt/Cashflow

-0.84

URGN Investor Care

Shares Dilution (1Y)

54.05%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202484.3M000
202368.0M72.5M77.3M82.7M
202254.1M57.7M62.4M64.4M
202119.3M31.9M39.8M48.0M
20207.2M8.8M10.3M11.8M
201902.7M4.2M5.7M
20188.6M9.0M1.5M1.1M
201715.2M12.8M10.5M8.2M
201600017.5M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of UroGen Pharma Ltd

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
schoenberg mark
sold
-67,401
13.08
-5,153
chief medical officer
Jun 10, 2024
schoenberg mark
acquired
-
-
10,000
chief medical officer
Mar 18, 2024
schoenberg mark
sold
-168,600
14.05
-12,000
chief medical officer
Feb 01, 2024
schoenberg mark
sold
-59,790
15.78
-3,789
chief medical officer
Feb 01, 2024
smith jason drew
sold
-78,789
15.78
-4,993
general counsel
Jan 31, 2024
smith jason drew
acquired
-
-
10,000
general counsel
Jan 31, 2024
kim dong
acquired
-
-
3,333
chief financial officer
Jan 31, 2024
schoenberg mark
acquired
-
-
6,666
chief medical officer
Jan 31, 2024
schoenberg mark
sold
-59,638
15.74
-3,789
chief medical officer

1–10 of 50

Which funds bought or sold URGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 16, 2024
SHIKIAR ASSET MANAGEMENT INC
reduced
-67.67
-319,000
180,000
0.05%
Jul 16, 2024
OAK RIDGE INVESTMENTS LLC
added
30.59
423,149
1,341,210
0.13%
Jul 10, 2024
NBC SECURITIES, INC.
added
48.05
4,000
10,000
-%
Jul 10, 2024
CWM, LLC
added
85.37
-
1,000
-%
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
sold off
-100
-5,000
-
-%
Jul 02, 2024
GAMMA Investing LLC
added
80.00
304
604
-%
Jul 01, 2024
Legal & General Group Plc
reduced
-2.89
-1,245
41,775
-%
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-855
-
-%
May 29, 2024
Opaleye Management Inc.
reduced
-15.62
-750,000
4,050,000
0.88%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
65.12
34,545
88,545
0.01%

1–10 of 50

Are Funds Buying or Selling URGN?

Are funds buying URGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own URGN
No. of Funds

Unveiling UroGen Pharma Ltd's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 24, 2024
cowen and company, llc
1.21%
5e+05
SC 13G
Jun 24, 2024
point72 asset management, l.p.
6.2%
2,569,826
SC 13G
May 08, 2024
blackrock inc.
4.6%
1,669,543
SC 13G/A
Feb 22, 2024
arkin moshe
4.44%
1,369,315
SC 13D/A
Feb 14, 2024
ra capital management, l.p.
9.99%
3,083,558
SC 13G/A
Feb 14, 2024
great point partners llc
8.49%
2,620,545
SC 13G/A
Feb 14, 2024
menora mivtachim holdings ltd.
7.46%
2,303,031
SC 13G/A
Feb 14, 2024
rtw investments, lp
5.6%
1,726,808
SC 13G
Feb 13, 2024
stonepine capital management, llc
0%
0
SC 13G/A
Feb 02, 2024
blackrock inc.
5.6%
1,719,304
SC 13G

Recent SEC filings of UroGen Pharma Ltd

View All Filings
Date Filed Form Type Document
Jul 09, 2024
ARS
ARS
Jul 01, 2024
DEFA14A
DEFA14A
Jul 01, 2024
DEF 14A
DEF 14A
Jun 24, 2024
SC 13G
Major Ownership Report
Jun 24, 2024
SC 13G
Major Ownership Report
Jun 18, 2024
8-K
Current Report
Jun 18, 2024
424B5
Prospectus Filed
Jun 17, 2024
424B5
Prospectus Filed
Jun 13, 2024
8-K
Current Report
Jun 11, 2024
4
Insider Trading

Peers (Alternatives to UroGen Pharma Ltd)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

UroGen Pharma Ltd News

Latest updates
American Banking and Market News7 hours ago
Seeking Alpha13 Jun 202407:00 am

UroGen Pharma Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Revenue-20.2%18,781,00023,530,00020,852,00021,139,00017,192,00018,092,00016,097,00016,604,00013,564,00016,174,00011,351,00013,032,0007,485,0007,966,0003,461,000372,000297,600223,200148,80074,400-
Cost Of Revenue-24.4%1,728,0002,286,0002,367,0002,443,0002,265,0002,263,0002,020,0001,846,0001,525,0001,589,0001,244,0001,427,000897,000652,000309,00048,000-----
Gross Profit-19.7%17,053,00021,244,00018,485,00018,696,00014,927,00015,829,00014,077,00014,758,00012,039,00014,585,00010,107,00011,605,0006,588,0007,314,0003,152,000324,000---18,000-
  S&GA Expenses11.2%27,299,00024,551,00021,755,00022,494,00024,474,00021,634,00019,071,00020,833,00021,300,00021,418,00021,624,00022,304,00022,189,00022,163,00022,065,00024,018,00021,973,00019,745,00013,972,00013,775,00012,552,000
  R&D Expenses37.1%15,494,00011,302,00010,230,00011,584,00012,498,00014,477,00013,093,00012,640,00012,696,00013,082,00011,923,00012,124,00010,513,00012,405,00010,211,0008,106,00016,588,00020,094,0009,481,0009,996,00011,465,000
EBITDA Margin-0.3%-1.18-1.18-1.34-1.47-1.61-1.66-1.70-1.93-2.04-2.26-2.72-3.36-5.85--------
Income Taxes-98.6%54,0003,854,000-9,00054,00021,000689,000709,00032,000325,0001,137,000-312,000-3,374,000-------
Earnings Before Taxes-45.4%-32,232,000-22,162,000-21,888,000-24,082,000-30,192,000-28,180,000-25,122,000-26,659,000-28,067,000-27,315,000-30,211,000-25,910,000-25,935,000-27,152,000-28,816,000-31,349,000-----
EBT Margin-0.2%-1.19-1.19-1.35-1.48-1.62-1.68-1.72-1.95-2.06-2.28-2.74-3.38-5.87--------
Net Income-24.1%-32,286,000-26,016,000-21,879,000-24,136,000-30,213,000-28,869,000-25,831,000-26,691,000-28,392,000-28,452,000-30,211,000-26,222,000-25,935,000-30,526,000-28,816,000-31,349,000-37,793,000-38,973,000-22,252,000-22,477,000-23,716,000
Net Income Margin-0.1%-1.24-1.24-1.36-1.50-1.64-1.71-1.75-1.97-2.09-2.31-2.83-3.49-6.05--------
Free Cashflow-143.1%-31,735,000-13,052,000-17,399,000-20,289,000-25,830,000-21,765,000-17,765,000-24,262,000-24,021,000-20,272,000-18,670,000-19,014,000-27,688,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets12.5%20117819495.0011313612814616612013515497.00122140161167202227239252
  Current Assets16.3%19716918281.0096.0012912214016111412514093.00116129130122149160191248
    Cash Equivalents38.4%13195.0011920.0037.0055.0029.0081.0010544.0055.0063.0040.0053.0025.0036.0026.0050.0066.0090.00247
  Inventory27.7%7.006.005.005.005.004.005.005.005.005.004.003.003.002.001.001.00-----
  Net PPE-17.9%1.001.001.001.001.001.002.002.002.002.002.002.002.002.002.001.001.001.001.001.001.00
Liabilities-1.2%24124423623423022519218718311110397.0021.0026.0019.0018.0016.0022.0016.0014.0012.00
  Current Liabilities-15.6%26.0031.0026.0027.0025.0024.0019.0018.0019.0022.0020.0019.0017.0021.0018.0016.0014.0019.0014.0012.0010.00
  Long Term Debt-1.0%98.0099.0099.0098.0098.0098.0072.0071.0071.00------------
    LT Debt, Non Current-1.0%98.0099.0099.0098.0098.0098.0072.0071.0071.00------------
Shareholder's Equity38.5%-40.13-65.21---116-89.36---8.0032.0056.0076.0096.00121143150180211225240
  Retained Earnings-4.8%-711-679-653-631-607-577-548-522-495-467-438-408-382-356-326-297-265-228-189-166-144
  Additional Paid-In Capital9.3%671614611493491488485481479476470465459453446439416408400391384
Shares Outstanding11.2%36.0033.0031.0023.0023.0023.0023.0023.0023.0022.0022.0022.0022.00--------
Float----190---145---251---525---695-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-144.2%-31,735-12,996-17,299-20,274-25,807-21,752-17,612-24,199-23,996-20,070-18,476-18,945-27,401-21,242-25,080-23,929-35,635-26,000-12,528-14,555-17,934
  Share Based Compensation5.6%2,7562,6112,2242,2222,2862,3682,4402,8232,9495,3575,5156,0466,1956,5266,7637,1197,6178,0657,2437,2127,447
Cashflow From Investing219.2%13,518-11,3444013,7206,27023,108-35,493-15113,5969,12510,660-30,74015,02449,46513,23417,51413,0259,296-12,659-142,186-44.00
Cashflow From Financing136542.5%54,65740.00116,07714367125,3681,101-77.0070,742-32.00-16872,5154.0078.0061.0016,29890.002451,126373163,506
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

URGN Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue$ 18,781$ 17,192
Cost of revenue1,7282,265
Gross profit17,05314,927
Operating expenses:  
Research and development expenses15,49412,498
Selling, general and administrative expenses27,29924,474
Operating loss(25,740)(22,045)
Financing on prepaid forward obligation(5,660)(5,224)
Interest expense on long-term debt(2,447)(3,553)
Interest and other income, net1,615630
Loss before income taxes(32,232)(30,192)
Income tax expense(54)(21)
Net Loss(32,286)(30,213)
Statements of Comprehensive Loss  
Net loss(32,286)(30,213)
Other comprehensive income (loss)  
Unrealized gain (loss) on investments(49)62
Comprehensive Loss$ (32,335)$ (30,151)
Net loss per ordinary share - basic and diluted (in dollars per share)$ (0.97)$ (1.3)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)33,379,78623,279,951

URGN Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 131,439$ 95,002
Marketable securities32,60641,966
Restricted cash823821
Accounts receivable14,15815,443
Inventories7,2435,673
Prepaid expenses and other current assets10,49110,281
Total current assets196,760169,186
Non-current assets:  
Property and equipment, net566689
Restricted deposit226225
Right of use assets1,4431,671
Marketable securities4814,502
Other non-current assets1,0982,038
Total Assets200,574178,311
Current liabilities:  
Accounts payable and accrued expenses18,15816,538
Employee related accrued expenses4,98510,814
Other current liabilities3,1973,860
Total current liabilities:26,34031,212
Non-current liabilities:  
Prepaid forward obligation112,947109,722
Long-term debt97,59098,551
Long-term lease liabilities637844
Uncertain tax positions liability3,1943,194
Total Liabilities240,708243,523
Commitments and Contingencies (Note 18)
Shareholders' Deficit:  
Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 36,127,687 and 32,490,119 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively9989
Additional paid-in capital671,438614,035
Accumulated deficit(711,634)(679,348)
Accumulated other comprehensive loss(37)12
Total Shareholders' Deficit(40,134)(65,212)
Total Liabilities and Shareholders' Deficit$ 200,574$ 178,311
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
 CEO
 WEBSITEurogen.com
 INDUSTRYBiotechnology
 EMPLOYEES193

UroGen Pharma Ltd Frequently Asked Questions


What is the ticker symbol for UroGen Pharma Ltd? What does URGN stand for in stocks?

URGN is the stock ticker symbol of UroGen Pharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UroGen Pharma Ltd (URGN)?

As of Fri Jul 19 2024, market cap of UroGen Pharma Ltd is 571.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers. The fair value of UroGen Pharma Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of UroGen Pharma Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for URGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is UroGen Pharma Ltd a good stock to buy?

The fair value guage provides a quick view whether URGN is over valued or under valued. Whether UroGen Pharma Ltd is cheap or expensive depends on the assumptions which impact UroGen Pharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for URGN.

What is UroGen Pharma Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, URGN's PE ratio (Price to Earnings) is -5.48 and Price to Sales (PS) ratio is 6.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. URGN PE ratio will change depending on the future growth rate expectations of investors.